[Skip to Content]
[Skip to Content Landing]
Views 192
Citations 0
Comment & Response
September 11, 2019

Vein-First Ligation Procedure for Lung Cancer Surgery

Author Affiliations
  • 1Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China
JAMA Surg. Published online September 11, 2019. doi:10.1001/jamasurg.2019.3483

To the Editor There is still no agreement on whether vein-first ligation should be recommended for non–small cell lung cancer (NSCLC) surgery, and thoracic surgeons choose based on their own preferences and surgical habits. Some advocate vein-first ligation because it might reduce tumor cell dissemination, while others advocate artery-first ligation because it might decrease unnecessary blood loss.1,2 Previous literatures have drawn controversial conclusions in comparison of vein-first ligation and artery-first ligation and the only randomized clinical trial, to our knowledge, found no correlation between sequence of vessel ligation and survival of patients with NSCLC.3 Wei et al4 retrospectively compared the survival of patients with NSCLC receiving vein-first ligation and these receiving artery-first ligation via propensity score analysis and found that vein-first ligation procedure was significantly correlated with better survival compared with artery-first ligation, which was applausively supported by further randomized analysis comparing folate receptor–positive circulating tumor cells in peripheral blood between vein-first ligation procedure and artery-first ligation procedure. Therefore, with sufficient reasons, the authors recommended ligating vein first for NSCLC surgery.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×